Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias - PubMed
3 months ago
- #Alzheimer's disease
- #neurodegenerative dementias
- #biofluid biomarkers
- Biofluid biomarkers are transforming research and care in Alzheimer's disease (AD) and other neurodegenerative dementias.
- Recent developments include biomarkers for amyloid-β (Aβ), tau pathology, neurodegeneration, glial reactivity, α-synuclein, TDP-43, synaptic pathophysiology, and cerebrovascular disease.
- Improved technologies now enable detection of neurodegenerative markers in blood, complementing cerebrospinal fluid assays.
- Molecular phenotyping biomarkers can improve clinical evaluation and treatment monitoring for neurodegenerative diseases.
- Anti-Aβ monoclonal antibodies represent a breakthrough in targeting Aβ pathology in AD.
- The review provides practical guidance on interpreting and implementing biofluid biomarkers in clinical settings.